Ortho-hydroxy N-acyl hydrazone compounds for procaspase-3 activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticancer strategies face challenges in effectively activating procaspase-3 in cancer cells, particularly in those with defective apoptotic pathways, and existing compounds often have neurotoxicity and short half-lives, limiting their clinical efficacy.
Innovation Solution
Development of ortho-hydroxy N-acyl hydrazone compounds, such as Procaspase-Activating Compound 1 (PAC-1) and its analogues, which enhance procaspase-3 activity by chelating labile zinc, leading to apoptosis in cancer cells with elevated procaspase-3 levels, and are designed to be metabolically stable and less neurotoxic.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing compounds are used to activate procaspase-3, then apoptosis induction is achieved, but neurotoxicity occurs
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (ortho-hydroxy N-acyl hydrazone motif) that confer selective activity. The compounds are engineered to have high affinity for procaspase-3 while avoiding interaction with neuronal targets, achieving localized efficacy at the cancer cell procaspase-3 target without affecting neuronal function.
Solution Approach 2:
The patent employs parameter changes by optimizing molecular parameters such as the acyl group structure, hydrazone linkage, and ortho-hydroxy substitution pattern. These parameter optimizations enhance the compounds' metabolic stability and selectivity for procaspase-3, reducing neurotoxicity while maintaining apoptosis induction capability.
2Reliability
If existing compounds are used to activate procaspase-3, then cancer cell death is achieved, but compound half-life is short
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure parameters of the compounds, specifically incorporating metabolically stable scaffolds with the ortho-hydroxy N-acyl hydrazone motif. These structural parameter changes protect against metabolic degradation, extending the compound half-life from minutes to hours while preserving procaspase-3 activation and cancer cell killing efficacy.
3Adaptability or versatility
If direct procaspase-3 activation is used as therapy, then personalized cancer treatment is enabled, but compounds must be metabolically stable for clinical effectiveness
Solution Approach 1:
The patent applies local quality by designing compounds with a specific stable core structure (ortho-hydroxy N-acyl hydrazone) that resists metabolic degradation. This localized structural feature ensures the compounds maintain their composition stability in vivo, enabling their use as personalized cancer therapies in clinical settings.
Solution Approach 2:
The patent employs composite materials by combining the stable ortho-hydroxy N-acyl hydrazone motif with various acyl group compositions. This composite approach creates a family of metabolically stable compounds that can be tailored for different cancer types while maintaining the core stability feature necessary for clinical effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds induce significant apoptosis in cancer cells, including those resistant to standard chemotherapy, with enhanced metabolic stability and reduced neurotoxicity, demonstrating potential as safe and effective anticancer agents.
Implementation Method 1
enhance procaspase-3 activity by chelating labile zinc
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention provides compounds and compositions useful for the modulation of certain enzymes. The compounds and compositions can induce of cell death, particularly cancer cell death. The invention also provides methods for the synthesis and use of the compounds and compositions, including the use of compounds and compositions in therapy for the treatment of cancer and selective induction of apoptosis in cells.